CuraSen Presents Late-Breaking Phase 2 Data with CST-2032/CST-107 at Clinical Trials in Alzheimer’s Disease (CTAD) Conference
Oct 24, 2023 https://www.curasen.com/wp-content/uploads/2023/10/Poster-034-Harrison-CTAD-2023-FINAL2.pdf
Oct 24, 2023 https://www.curasen.com/wp-content/uploads/2023/10/Poster-034-Harrison-CTAD-2023-FINAL2.pdf
Aug 03, 2023 – $37.5 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $32.5 million, for second quarter 2023– Acquiring CHENODAL® and CHOLBAM®, advancing Mirum’s leadership in pediatric hepatology with a multi-product franchise– Four late-stage clinical trial data readouts expected later this year– Conference call to provide business updates today, August 3…
Aug 10, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,200 shares of common stock and 17,100 restricted stock units (“RSUs”) to six new employees under Mirum’s 2020 Inducement…
Sep 05, 2023 FOSTER CITY, Calif. & SAN DIEGO–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”). In…
Sep 06, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Visit the Investors and Media section of Mirum’s corporate website for webcast links and…
Sep 08, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on September 8, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 174,000 shares of common stock and 91,000 restricted stock units (“RSUs”) to 21 new employees under Mirum’s 2020 Inducement…